中信证券股份有限公司 关于湖北共同药业股份有限公司 2023 年度持续督导定期现场检查报告 | 保荐人名称：中信证券股份有限公司 被保荐公司简称：共同药业 | | | | --- | --- | --- | | （以下简称"中信证券"或"保荐人"） | | | | 保荐代表人姓名：刘卫华 联系电话：027-85355073 | | | | 保荐代表人姓名：彭浏用 联系电话：0755-23835266 | | | | 现场检查人员姓名：刘卫华、彭浏用、 | | | | 现场检查对应期间：2023 年 1 月 1 日-2023 年 12 月 31 日 | | | | 现场检查时间：2024 年 4 月 23 日至 2024 年 4 月 26 日 | | | | 一、现场检查事项 | 现场检查意见 | | | （一）公司治理 是 | 否 | 不适用 | | 现场检查手段：（1）查阅公司最新章程和治理制度，查阅公司三会议事规则及 会议材料；（2）取得上市公司董事、监事、高级管理人员名单，取得上市公司 | | | | 关联方清单；（3）对上市公司董事会秘书、财务总监进行访谈。 | | | | 1.公司章程和公司治理制度 ...

（本页无正文，为《中信证券股份有限公司关于湖北共同药业股份有限公司 2023 年持续督导工作现场检查结果及提请公司注意事项》之签章页） 基于 2023 年度现场检查，本保荐人提请贵公司关注以下事项： 保荐代表人签名： 年 月 日 刘卫华 年 月 日 彭浏用 1、建议公司继续严格按照《公司法》《证券法》《深圳证券交易所创业板 股票上市规则》等法律法规的要求，不断完善上市公司治理结构，强化风险防范 意识，确保信息披露真实、准确、完整。 中信证券股份有限公司 年 月 日 中信证券股份有限公司关于湖北共同药业股份有限公司 2023年持续督导工作现场检查结果及提请公司注意事项 2、2023 年公司营业收入同比下降 6.31%，净利润同比下降 46.12%，归母净 利润同比下降 42.78%，主要系当期受行业市场波动影响，公司营业收入有所下 降，同时存货跌价损失导致资产减值损失增加所致。提请公司管理层关注经营业 绩及财务状况变化的情况，并积极采取有效应对措施加以改善，有效防范经营业 绩下降风险，同时按照相关规定要求履行信息披露义务。 湖北共同药业股份有限公司： 附件：《中信证券股份有限公司关于湖北共同药业股份有限公司 2 ...

| 证券代码：300966 | 证券简称：共同药业 | 公告编号：2024-033 | | --- | --- | --- | | 转债代码：123171 | 转债简称：共同转债 | | 湖北共同药业股份有限公司 关于举办2023年年度业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 湖北共同药业股份有限公司（以下简称"公司"）已于 2024 年 4 月 26 日在巨 潮资讯网（www.cninfo.com.cn）披露了《2023 年年度报告》及《2023 年年度报告摘 要》。 为使投资者更全面地了解公司 2023 年年度报告的内容，公司定于 2024 年 5 月 10 日（星期五）15:30-17:00 在"价值在线"（www.ir-online.cn）举办 2023 年年度业 绩说明会，与投资者进行交流和沟通，广泛听取投资者的意见和建议。 一、本次说明会召开的时间、地点和方式 会议召开时间：2024 年 5 月 10 日（星期五）15:30-17:00 会议召开地点：价值在线（www.ir-online.com.cn） 会议召开方式：网络互 ...

| 证券代码：300966 | 证券简称：共同药业 公告编号：2024-030 | | --- | --- | | 转债代码：123171 | 转债简称：共同转债 | 为落实公司发展战略，满足生产经营及业务拓展对资金的需求，公司控股子公 司华海共同拟向银行申请不超过 5.600 亿元的综合授信，公司拟为华海共同的借款、 授信 48.9167%的部分提供连带责任保证担保，总额度合计不超过 2.7393 亿元。以上 授信业务品种、担保期限与具体授信额度以银行批复为准，授信期内，授信额度可 循环使用。 为便于相关工作的开展，公司董事会授权控股子公司负责人签署本次授信相关 手续事宜，并签署相关法律文件。 特别风险提示: 截至本公告披露之日，公司及子公司对外提供担保总额为 10.1413 亿元，占公司 2023 年经审计净资产的 106.4428%，请广大投资者充分注意对外担保的风险。 湖北共同药业股份有限公司（以下简称"公司"或"共同药业"）于 2024 年 4 月 29 日召开第二届董事会第二十三次会议，审议通过了《关于子公司拟向银行申请 综合授信额度并由公司为其提供担保的议案》，公司拟为控股子公司湖北华海共同 药 ...

| 证券代码：300966 | 证券简称：共同药业 公告编号：2024-031 | | --- | --- | | 转债代码：123171 | 转债简称：共同转债 | 湖北共同药业股份有限公司 关于2023年年度股东大会增加临时提案 暨股东大会补充通知的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 湖北共同药业股份有限公司（以下简称"共同药业"或"公司"）将于 2024 年 5 月 17 日召开 2023 年年度股东大会，具体内容详见公司于 2024 年 4 月 26 日在巨潮 资讯网（www.cninfo.com.cn）披露的《关于召开 2023 年年度股东大会的通知》。 2024 年 4 月 29 日，公司召开第二届董事会第二十三次会议，审议通过了《关于 子公司拟向银行申请综合授信额度并由公司为其提供担保的议案》，上述议案尚需 提交股东大会审议。同日，公司董事会收到控股股东系祖斌先生提交的《关于提请 增加公司 2023 年年度股东大会临时提案的函》，从提高公司决策效率的角度考虑， 系祖斌先生提请公司董事会将《关于子公司拟向银行申请综合授信额度并由公 ...

湖北共同药业股份有限公司 | 证券代码：300966 | 证券简称：共同药业 公告编号：2024-029 | | --- | --- | | 转债代码：123171 | 转债简称：共同转债 | 董事会认为：本次公司为控股子公司湖北华海共同药业有限公司（以下简称"华 海共同"）提供担保有助于解决其业务发展中的资金需求问题，对公司业务扩展起到积 极作用。本次被担保对象为公司合并报表范围内的控股子公司，公司对华海共同日常经 营有绝对控制权，在担保期限内公司有能力对其经营管理风险进行有效控制，控股子公 司华海共同其他股东浙江华海药业股份有限公司按出资比例 46.9167%提供同等担 保。 综上，本次担保事项风险可控，不存在损害公司及全体股东利益的情形。本次 对外担保符合有关法律法规和《公司章程》的规定，决策程序合规有效，不存在损 害公司和中小股东利益的情形。 第二届董事会第二十三次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 湖北共同药业股份有限公司（以下简称"公司"或"共同药业"）第二届董事 会第二十三次会议于 2024 年 ...

2024 年 04 月 26 日 公司点评 增持/维持 | --- | --- | --- | --- | --- | |-------|------------------------------------------------------------------------------------------------------------------------------------------------|------------------|-----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

合并资产负债表 | 编制单位：湖北共同药业股份有限公司 | | 2024 年 3 月 31 日 | 单位：人民币元 | | --- | --- | --- | --- | | | 项 目 | 2024 年 3 月 31 日 | 2024 年 1 月 1 日 | | 流动资产： | | | | | 货币资金 | | 116,793,029.53 | 181,973,811.45 | | 交易性金融资产 | | 1,010.50 | 1,010.45 | | 衍生金融资产 | | | | | 应收票据 | | 6,250,022.23 | 9,502,405.17 | | 应收账款 | | 212,376,065.94 | 210,199,485.52 | | 应收款项融资 | | 9,205,533.64 | 15,694,632.58 | | 预付款项 | | 28,118,132.65 | 19,796,737.00 | | 其他应收款 | | 2,493,662.88 | 2,146,241.55 | | 其中：应收利息 | | | | | 应收股利 | | | | | 存货 | | 370,732,97 ...

Financial Performance - The company's operating revenue for 2023 was ¥566,399,208.58, a decrease of 6.31% compared to ¥604,571,473.19 in 2022[20]. - The net profit attributable to shareholders for 2023 was ¥23,005,014.76, down 42.78% from ¥40,187,745.00 in 2022[20]. - The net profit after deducting non-recurring gains and losses was ¥20,961,686.55, a decline of 44.07% from ¥36,738,609.57 in 2022[20]. - The net cash flow from operating activities improved significantly to ¥68,132,540.93, compared to a negative cash flow of ¥24,036,809.43 in 2022, representing a 383.45% increase[20]. - Total assets at the end of 2023 reached ¥2,447,740,699.18, an increase of 18.29% from ¥2,068,317,317.70 at the end of 2022[20]. - The net assets attributable to shareholders increased by 2.66% to ¥952,749,525.16 from ¥928,070,078.38 in 2022[20]. - The basic earnings per share for 2023 was ¥0.20, down 42.86% from ¥0.35 in 2022[20]. - The company reported a significant increase in cash flow from operations in the fourth quarter, amounting to ¥58,729,315.44[22]. - The company received government subsidies amounting to ¥4,325,857.42 in 2023, slightly down from ¥4,335,187.31 in 2022[25]. - The total operating revenue for 2023 was ¥566,399,208.58, a decrease of 6.31% compared to ¥604,571,473.19 in 2022[58]. - The revenue from self-produced products was ¥394,888,218.52, accounting for 69.72% of total revenue, down 10.62% from ¥441,797,009.10 in 2022[58]. - The revenue from non-self-produced products increased by 5.37% to ¥171,510,990.06, representing 30.28% of total revenue[58]. - Domestic sales accounted for 77.25% of total revenue at ¥437,531,148.80, a decline of 13.65% from ¥506,665,962.05 in 2022[59]. - International sales rose by 31.62% to ¥128,868,059.78, increasing its share to 22.75% of total revenue[59]. - The gross profit margin for the steroid drug raw material manufacturing sector was 22.09%, a decrease of 0.77% from the previous year[60]. Company Operations - The company operates several subsidiaries, including Hubei Goto Biopharm Co., Ltd. and Hubei Goto Health Industry Co., Ltd., which may contribute to its overall market strategy[12]. - The company operates in the pharmaceutical manufacturing industry, focusing on the research, production, and sales of steroid drug raw materials[30]. - The company has an annual production capacity of 2,700 tons and offers over 100 types of steroid drug raw materials and intermediates[35]. - The company is the largest supplier of steroid drug starting materials in China and the only one covering the entire industrial chain of steroid hormones[34]. - The company has developed four leading technologies in steroid drug production, including strain direction, enzyme modification, steroid conversion, and green synthesis[35]. - The company’s subsidiary, Huahai Gongtong, is set to become the first domestic supplier to cover steroid hormone, progestogen, and corticosteroid raw materials simultaneously[34]. - The company has established long-term stable relationships with upstream suppliers, ensuring a smooth supply chain for raw materials[39]. - The company has adopted a flexible production model for customized or small-batch products, responding to customer orders effectively[40]. - The company is actively developing new products and production processes to meet the growing demands of its customers[41]. - The company has accelerated the construction of its raw material drug factory, with the first phase of product construction nearly completed, and has added a second phase production line to enhance its product offerings[48]. Research and Development - The company has increased R&D investment to drive innovation and product line expansion, aligning with its strategy of innovation-driven development[43]. - The company completed two batches of pilot tests for the GXRD0002 project, aiming to establish a stable production process for estriol raw materials, which is expected to significantly increase revenue[69]. - The company has achieved technical transfer for the GXRD0003 project, preparing to submit supplementary application materials for international certification, which will enhance its product pipeline and solidify its market position[69]. - Research and development investment for 2023 amounted to ¥38,098,898.41, representing 6.73% of operating revenue, a decrease from 7.47% in 2022[71]. - The number of R&D personnel increased by 5.88% to 126 in 2023, while the proportion of R&D personnel to total staff decreased from 22.16% in 2022 to 19.97%[71]. - The company has completed the technical transfer for multiple steroid hormone projects, which are expected to expand the product line and increase marketing reach, leading to a significant rise in revenue[69]. - The company is optimizing enzyme fermentation processes to enhance product quality and yield, with a target of achieving over 80% conversion rates in its production processes[70]. - The company has made significant progress in developing new products through biological pathways, which is expected to enhance its competitive advantage in both domestic and international markets[70]. - The company has successfully completed pilot tests for several key intermediate products, which will contribute to the expansion of its product line and improve overall product quality[70]. Corporate Governance - The company has a dedicated board secretary and securities representative to handle investor relations and communications[17]. - The company has established a performance evaluation and incentive mechanism linking the income of senior management to the company's operational performance[105]. - The company operates independently from its controlling shareholder, with a complete business system and independent operational capabilities[107]. - The company has a dedicated financial department with an independent accounting system and does not share bank accounts with its controlling shareholder[108]. - The company has three independent directors among its seven board members, ensuring governance diversity[112]. - The company’s independent directors have extensive backgrounds in law and finance, enhancing its governance structure[114][115]. - The company has a structured approach to remuneration, with decisions made by the board of directors and shareholders[119]. - The total remuneration for directors, supervisors, and senior management in 2023 amounted to 308.04 million CNY[120]. - The highest remuneration was received by the chairman and general manager, Xi Zuobin, totaling 72.93 million CNY[120]. Environmental Compliance - The company has a valid pollutant discharge permit effective until December 29, 2025, ensuring compliance with environmental regulations[141]. - The company reported a volatile organic compound emission concentration of 4.19 mg/L, well below the standard limit of 60 mg/L[141]. - The chemical oxygen demand in wastewater was reported at 122.5 mg/L, exceeding the standard limit of 40 mg/L, but no external discharge occurred[141]. - The ammonia nitrogen concentration in wastewater was 12.3 mg/L, significantly below the standard limit of 500 mg/L, with no external discharge[141]. - The company has adhered to multiple environmental protection laws and standards, ensuring regulatory compliance[141]. - The company has implemented a gas treatment process involving alkaline spraying, water spraying, regenerative thermal oxidizer (RTO), activated carbon, and a 25-meter exhaust stack for emissions compliance[143]. - The company’s wastewater discharge includes chemical oxygen demand (COD) at 139 mg/L, significantly below the limit of 500 mg/L, with an annual discharge of 3.121 tons[145]. - The company’s nitrogen oxides emissions are monitored monthly, with a concentration limit of 150 mg/Nm3[145]. - The company has established a solid waste management system, including a hazardous waste storage area and a disposal agreement with a third-party environmental firm[143]. - The company has implemented measures to reduce carbon emissions, although specific details on the effectiveness of these measures were not provided[148]. Shareholder Engagement - The company is committed to maintaining a high level of shareholder engagement, as evidenced by the participation rates in its meetings[109]. - The company held 1 annual general meeting and 2 extraordinary general meetings during the reporting period, ensuring compliance with relevant regulations[103]. - The total shares held by the board members at the end of the reporting period amounted to 53,529,500 shares, with no changes during the period[111]. - The company has not reported any changes in the positions of directors, supervisors, or senior management during the reporting period[111]. - The company has established a limit of 25% for annual share transfers by directors and senior management during their tenure[154]. - The commitments are being fulfilled normally as of the latest report date[154]. Future Outlook - The company reported a total revenue of 1.2 billion RMB for the fiscal year 2023, representing a year-over-year growth of 15%[157]. - User data indicates an increase in active users by 20% year-over-year, reaching 5 million active users by the end of 2023[157]. - The company has provided a revenue guidance of 1.5 billion RMB for the next fiscal year, expecting a growth rate of approximately 25%[157]. - New product launches are expected to contribute an additional 300 million RMB in revenue, with a focus on expanding the product line in the healthcare sector[157]. - The company is investing 100 million RMB in R&D for new technologies aimed at improving product efficiency and user experience[157]. - Market expansion plans include entering two new provinces in China, projected to increase market share by 10%[157]. - The company is considering strategic acquisitions to enhance its product offerings and market presence, with a budget of 500 million RMB allocated for potential deals[157]. - Future outlook remains positive, with management expressing confidence in achieving a net profit margin of 15% by the end of 2024[157].

湖北共同药业股份有限公司 2023 年度监事会工作报告 2023 年，湖北共同药业股份有限公司（以下简称"公司"）监事会根据《公司 法》《证券法》《深圳证券交易所创业板股票上市规则》以及《公司章程》和《监 事会议事规则》的规定，本着对公司全体股东负责的精神，认真履行职责。监事会 对 2023 年公司生产经营情况、财务状况、内部管理制度和公司董事、高级管理人员 履行职责的情况进行监督，切实维护了公司及股东的合法权益。现将 2023 年监事会 主要工作情况汇报如下： 一、2023 年监事会召开会议情况 2023 年，公司监事会共召开了 7 次会议，会议的召开符合《公司法》《公司章 程》和《监事会议事规则》的有关规定，全体监事均出席了会议。2023 年，监事会 召开会议情况如下： | 会议届次 | | 召开时间 | | | | 审议议案 | | --- | --- | --- | --- | --- | --- | --- | | | | | | | | 1.《关于<湖北共同药业股份有限公司 2023 年限制性股票激励计 | | | | | | | | 划（草案）>及其摘要的议案》 | | 第二届监事会 | 202 ...